Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

uniQure « Terug naar discussie overzicht

Sanfilippo B

23 Posts, Pagina: « 1 2 | Laatste

Omlaag ↓

flosz 14 juli 2017 13:54

Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial

Summary
Background
Mucopolysaccharidosis type IIIB syndrome (also known as Sanfilippo type B syndrome) is a lysosomal storage disease resulting in progressive deterioration of cognitive acquisition after age 2–4 years. No treatment is available for the neurological manifestations of the disease. We sought to assess the safety and efficacy of a novel intracerebral gene therapy.
Methods
Local regulatory authorities in France allowed inclusion of up to four children in this phase 1/2 study. Treatment was 16 intraparenchymal deposits (four in the cerebellum) of a recombinant adenoassociated viral vector serotype 2/5 (rAAV2/5) encoding human a-N-acetylglucosaminidase (NAGLU) plus immunosuppressive therapy. We assessed tolerance, neurocognitive progression, brain growth, NAGLU enzymatic activity in CSF, and specific anti-NAGLU immune response for 30 months after surgery. This trial is registered with EudraCT, number 2012-000856-33, and the International Standard Clinical Trial Registry, number ISRCTN19853672.
Findings
Of seven eligible children, the four youngest, from France (n=2), Italy (n=1), and Greece (n=1), aged 20, 26, 30, and 53 months, were included between February, 2012, and February, 2014. 125 adverse events were recorded, of which 117 were treatment emergent and included six classified as severe, but no suspected unexpected serious adverse drug reactions were seen. Vector genomes were detected in blood for 2 days after surgery. Compared with the natural history of mucopolysaccharidosis type III syndromes, neurocognitive progression was improved in all patients, with the youngest patient having function close to that in healthy children. Decrease in developmental quotient was -11·0 points in patient one, -23·0 in patient two, -29·0 in patient three, and -17·0 in patient four, compared with -37·7 in the natural history of the disease. NAGLU activity was detected in lumbar CSF and was 15–20% of that in unaffected children. Circulating T lymphocytes that proliferated and produced tumour necrosis factor a upon ex-vivo exposure to NAGLU antigens were detectable at 1–12 months and 3–12 months, respectively, but not at 30 months in three of four patients.
Interpretation
Intracerebral rAVV2/5 was well tolerated and induced sustained enzyme production in the brain. The initial specific anti-NAGLU immune response that later subsided suggested acquired immunological tolerance. The best results being obtained in the youngest patient implies a potential window of opportunity. Longer follow-up is needed to further assess safety outcomes and persistence of improved cognitive development.
Funding
Association Française Contre les Myopathies, Vaincre les Maladies Lysosomales, Institut Pasteur, and UniQure.

$QURE MPSIIIB #SanfilippoB twitter.com/mauriceontw/status/885800... services.corporate-ir.net/SEC/Documen...
Zie P$'s post: www.iex.nl/Forum/Topic/1286603/289/Wa...

Bijlage:

flosz 8 november 2017 14:20

Veranderingen sanB trial: vermelding Venn Life Sciences nog niet eerder gezien imho. Ook een nieuwe Principal Investigator (was Tardieu). clinicaltrials.gov/ct2/show/NCT03300453

flosz 30 november 2019 12:53

Update (Jan.2019) on Phase I/II Clinical Trial of Intracerebral Administration of rAAV2/5hNAGLU Vector in Children with MPSIIIB www.youtube.com/watch?v=3aaKv_gcab4
twitter.com/floszcrxl/status/12007288...

Bijlage:

23 Posts, Pagina: « 1 2 | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX	860,01	-5,35	-0,62%	19 apr
AMX	921,43	-5,17	-0,56%	19 apr
ASCX	1.182,36	-7,47	-0,63%	19 apr
BEL 20	3.827,75	+1,17	+0,03%	19 apr
Germany40^	17.714,20	-23,16	-0,13%	19 apr
US30^	37.851,00	0,00	0,00%	19 apr
US500^	4.960,72	0,00	0,00%	19 apr
Nasd100^	17.004,48	0,00	0,00%	19 apr
Japan225^	37.028,48	0,00	0,00%	19 apr
WTI	82,10	+0,02	+0,02%	19 apr
Brent	87,14	+0,15	+0,17%	19 apr
EUR/USD	1,0655	+0,0012	+0,11%	19 apr
BTC/USD	64.387,73	+799,96	+1,26%	19 apr
Gold spot	2.392,50	0,00	0,00%	19 apr